Tag: oxycontin

  • Dopesick: An Interview with Beth Macy

    Dopesick: An Interview with Beth Macy

    It takes the average user eight years and five to six treatment attempts just to achieve one year of sobriety. And in an era of fentanyl and other even stronger synthetic opioids, many users don’t have eight years.

    As recently as a few years ago, the opioid crisis could be referred to as a “silent epidemic,” perhaps in part due to its degrading nature. Opioid addiction is frequently described using metaphors of slavery, or enslavement, and those within its clutches are liable to feel acutely ashamed. No longer, however, is it possible to argue that the scourge of opioid addiction is being overlooked.

    No doubt that is partly due to the growing enormity of the problem. For each of the past several years, more people have died from drug overdoses than American service members were killed during the entire Vietnam War.

    Meanwhile, energetic and compassionate journalists have been doing outstanding work, covering the crisis from various vantages. Chief among them is Beth Macy, a New York Times-bestselling author, who first began noticing the effects of opioid addiction as a reporter for the Roanoke Times, where she worked for 25 years until 2014. Now she is out with Dopesick: Dealers, Doctors, and the Drug Company That Addicted America. Gracefully written and deeply reported, Dopesick should act as a vade mecum — a handbook, a guide, an essential introduction — for anyone who may be seeking insight into the deadliest and most vexing drug epidemic in American history. 

    Beth spoke to The Fix over email:

    The Fix: The first chapters of your book, on the origins of the opioid crisis, cover some material that others have explored (most notably Barry Meier, in Pain Killer: An Empire of Deceit and the Origin of America’s Opioid Epidemic). Still, I don’t have the sense that many people are aware of the role that Purdue Pharma played in setting off current epidemic. Briefly, what is their culpability? And why do think their crimes aren’t crimes better known? 

    Beth Macy: I think Meier’s book, Pain Killer, was too early, initially published in 2003, and it was largely set in central Appalachia — a politically unimportant place. Also, let’s not overlook the role that Purdue took in stifling Meier. As I write in the book, company officials had him removed from the beat after his book came out, arguing that he now had a financial stake in making Purdue look bad.

    After the 2007 plea agreement, in which the company’s holding company, Purdue Frederick, pled guilty to criminal misbranding charges and its top three executives to misdemeanor versions of that crime, Purdue and other opioid makers and distributors spent 900 million dollars on political lobbying and campaigns. Purdue continued selling the original OxyContin formula until it was reformulated to be abuse-resistant in 2010, continued for years after that pushing the motion that untreated pain was really the epidemic that Americans should be concerned about. Their culpability in seeding this epidemic is huge.

    You weren’t able to talk directly with any of the Purdue executives who made fortunes from OxyContin, and who criminally misled the public about its addictive potential. But you spent an afternoon interviewing Ronnie Jones, who is currently serving a lengthy prison sentence for running a major heroin distribution operation in West Virginia. How were Jones’s crimes (and his rationalizations for his behavior) different from those of the Purdue executives you wrote about?

    Great question. Jones refused to see that he brought bulk heroin to a rural community in ways that overwhelmed families and first responders in the region with heroin addiction; he told me he believed he was providing a service — his heroin did not have fentanyl in it, he argued, and it was cheaper than when people ran up the heroin highway to get it in Baltimore (and safer because they could stay out of high-crime places).

    At the 2007 sentencing hearing, Purdue executives and their lawyers repeatedly claimed they had no knowledge of crimes that were happening several rungs down the ladder from them; that the government had not proved their culpability in the specific crimes. According to new Justice Department documents unearthed and recently published by The New York Times , that was simply not true. For two decades, Purdue leaders blamed the users for misusing their drug; they refused to accept responsibility for criminal misbranding that resulted in widespread addiction and waves of drug-fueled crime that will be felt in communities and families for generations to come.

    You quote a health care professional who said that previous drug epidemics began waning after enough people finally got the message: “Don’t mess with this shit, not even a little bit.” That provoked a thought: Shouldn’t we be long past this point with opioids? On the one hand, I’m enormously sympathetic to anyone who is struggling with addiction. But it’s frustrating to realize that the opioid crisis is still building. Why aren’t more people as risk-averse about heroin as they obviously should be?

    The crisis is still building because the government’s response to it has largely been impotent. And it’s been festering for two decades. Opioid addiction doesn’t just go away. It takes the average user eight years and five to six treatment attempts just to achieve one year of sobriety. And in an era of fentanyl and other even stronger synthetic opioids, many users don’t have eight years. I hope we will soon get to the point of public education where no young person “messes with this shit, not even once,” but right now we still have 2.6 million people with opioid use disorder. Even though physicians have begun prescribing less, we still have all these addicted people who should be seen as patients worthy of medical care, not simply criminals. Too often that doesn’t happen until we’re sitting in their funeral pews.

    One of the women you write about, Tess Henry, slid down a long road. You got to know her and her family quite well, over a number of years. And some of the other stories in this book are just as heartbreaking.

    It was a lot of pain to absorb and process, yes. And yet my heartache was nothing at all compared to what these families are going through.

    In a couple instances, Tess reached out to you directly, asking you for help. How did you calculate how to respond?

    I took it case by case; I just went with my gut, and I got input from my husband and trusted friends along the way. I decided it was okay to drive Tess around to [Narcotics Anonymous] meetings, recording our interviews as I drove, with her permission. But it wasn’t okay when she texted me late one night to come get her from a drug house. (I referred her plea to her mother and recovery coach instead.)

    I occasionally gave her mother unsolicited advice because I cared about her and I cared about Tess, and I felt I had access to objective information about medication-assisted treatment that Patricia didn’t have. When Tess was murdered on Christmas Eve, I put my notes away and for several days just focused on being a friend to her mom. But I did accompany the family to the funeral home when they made arrangements (taking occasional notes), and I was there in the room of the funeral parlor with her mom and her grandfather when they said goodbye to her. It took funeral technicians two days to prepare her body for that. It was the most heartbreaking scene I’ve ever witnessed. There was no need to take notes in that moment. I will never forget it as long as I live. I said a tearful goodbye to our poet, too.

    Was there ever a risk, over the course of your reporting, of becoming too involved in the lives and predicaments of the people you were writing about? 

    Always there’s a risk, but I’ve been doing this for more than 30 years now, and I know that my greatest skill — which is that I get close to people — can also be my Achilles. When I trust my gut and try to do the right thing — always also getting advice from editor and reporter friends along the way, including my husband, who is just so smart and so spot-on always — it usually works out.

    I’m grateful to have read Dopesick. But at various times it left me infuriated, appalled, and depressed. Can you leave us with anything to be hopeful about? 

    There are some pretty heartening grassroots efforts that I spotlight at the book’s end, mostly involving providing access to treatment and harm-reduction services. And Virginia just became the 33rd state to approve Medicaid under the Affordable Care Act, which will help 300,000 to 400,000 people in the commonwealth have access to substance use disorder services. Seventeen more states to go! There is so much more work to be done, especially in Appalachia, where overdose deaths are highest and resistance to harm reduction programs (easy-access MAT and syringe exchange and recovery) can be severe. My goal is that Dopesick not only educates people but also mobilizes them to care and create what Tess Henry called “urgent care for the addicted” services in their own hometowns.

    View the original article at thefix.com

  • Demi Lovato’s Alleged Dealer Claims She Knew Pills Were Risky

    Demi Lovato’s Alleged Dealer Claims She Knew Pills Were Risky

    Friends of Lovato’s said they became concerned when they learned that the singer had begun spending time with Brandon Johnson in April.

    The man who allegedly provided singer Demi Lovato with the pills that she overdosed on in July said that he warned the singer that the pills were “aftermarket” and that she knew the risks with taking them. 

    Brandon Johnson told TMZ that Lovato texted him at 4 a.m. on the day that she overdosed, asking him to come over. Johnson said that he brought pills over and warned Lovato that they were not pharmaceuticals, so they were likely to be stronger.

    TMZ has previously reported that Lovato’s overdose was likely caused by OxyContin pills laced with fentanyl and that Johnson got the pills from Mexico. 

    Johnson insinuated to TMZ that they had done drugs together in the past and that they had a sexual relationship.

    After freebasing the pills together, Johnson told TMZ that he and Lovato watched true crime TV. When he left around 7 or 8 a.m. Lovato was asleep but not in distress, he said. 

    However, when Lovato’s assistant arrived around 11:30 a.m. the singer was in respiratory distress. Paramedics responded and administered Narcan to the pop star who went on to spend two weeks in the hospital before going to rehab. 

    Johnson said that Lovato’s overdose had made him realize how dangerous the pills can be. He added that the incident was “a wake up call for [Lovato].”

    Friends of Lovato’s have told TMZ that Johnson is “bad news” and that they were worried when they learned that the singer had begun hanging around with him in April.

    Just a month before the two connected, Johnson was reportedly arrested with $10,000, a loaded semi-automatic handgun and drugs. However, it seems to have been common knowledge with the singer’s circle that Johnson was dealing Lovato pills. 

    After her overdose, Lovato took to Instagram to discuss her overdose. 

    “I have always been transparent about my journey with addiction,” she wrote. “What I’ve learned is that this illness is not something that disappears or fades with time. It is something I must continue to overcome and have not done yet.”  

    She thanked the hospital that cared for her, and her friends and family

    “I now need time to heal and focus on my sobriety and road to recovery. The love you have all shown me will never be forgotten and I look forward to the day where I can say I came out on the other side. I will keep fighting.”

    View the original article at thefix.com

  • New York Sues Purdue Pharma Over Opioid Marketing

    New York Sues Purdue Pharma Over Opioid Marketing

    New York plans to work with other states that are investigating opioid manufacturers and distributors in the US.

    This week, New York became the 27th state to sue Purdue Pharma, a producer of OxyContin, for alleged fraud and deception in its marketing of opioids.

    The Wall Street Journal reported that Purdue is the only defendant listed in the lawsuit, driven by the administration under Governor Andrew Cuomo and New York Attorney General Barbara Underwood.

    The complaint was filed in Suffolk County Supreme Court and charged that a community flooded with opioids has been devastated while Purdue has increased profits and prescriptions.

    The suit charges that as of 2016, over 75% of New York’s opioid overdose deaths were caused by painkillers which include Purdue’s product, OxyContin.

    Governor Cuomo was quoted in Insurance Journal as saying, “The opioid epidemic was manufactured by unscrupulous distributors who developed a $400 billion industry pumping human misery into our communities. This lawsuit sends a clear message (to those) who mislead the public to increase their profit margins that we will hold you accountable.”

    Purdue released a response which called New York’s allegations false, while citing that the company also shares the state’s concerns about the opioid crisis.  

    Purdue noted that the U.S. Food and Drug Administration (FDA) “continues to approve” of scientific and medical information it provides to physicians.

    In the suit, New York is seeking civil fines to be levied against Purdue. The state asks to recoup profits the drug company has made and pay fines for what they allege in the Insurance Journal is “criminal nuisance.”

    In 2007, Purdue and three executives pleaded guilty to misbranding OxyContin. The company was charged with $634.5 million after a U.S. Department of Justice investigation.

    The New York lawsuit against Purdue is part of a trend; a number of U.S. states are suing opioid makers and distributors over opioid marketing.

    New York joined 26 other states, and Puerto Rico, in suing Purdue over their allegedly deceptive opioid marketing practices and the resulting health crisis.

    Cuomo released a statement published in the Wall Street Journal that the country is fed up with the practice of pharmaceutical companies purposefully creating addiction for the purpose of profit.

    Barbara Underwood in the Wall Street Journal said that the complaint is only New York’s first step toward holding pharmaceutical companies responsible. “Our work won’t stop with this lawsuit,” she said.

    New York plans to work with other states to investigate United States opioid manufacturers and distributors.

    View the original article at thefix.com

  • New Book "Dopesick" Explores The Opioid Crisis From All Angles

    New Book "Dopesick" Explores The Opioid Crisis From All Angles

    “My goal with this book was not to just show you how we got here and what it’s going to take to get out of it but also to inspire people to care,” says author Beth Macy.

    Journalist Beth Macy set out with a mission: to address the opioid epidemic from every possible angle. 

    In her new book, Dopesick: Dealers, Doctors and the Drug Company that Addicted America, she does that through examining the opioid epidemic from the very beginning to its current state. 

    According to NPR, Macy begins the book by detailing the story of Jesse, a 19-year-old whose struggles began with pills and ended with heroin. Jesse is one of the many lives taken at the hands of the opioid crisis.

    “He was one of these rambunctious kids who rarely napped,” Macy told NPR. “As a little boy, he would fall asleep with toys still in his hands. And early on, they put him on ADHD medication. He also had some football and snowboarding injuries when he was 15 and 16 and was prescribed opioid painkillers then.

    “His mother isn’t exactly sure at what point he became hooked, at what point he realized he was dope sick. But he knew he could trade his ADHD medicine for the opioid pills. And one thing led to another. When the pills got harder to get because of doctors cracking down on prescribing, that’s when the heroin started coming in.”

    Initially, Macy tells CBS, Jesse’s mother was unaware of the depths her son’s use had gone to.

    “She said something else that I heard a lot, which is ‘I thought it was just pills,’ and it had progressed to heroin unbeknownst to her, and he never missed a day at work,” Macy told CBS.

    As journalists do, Macy comes at the opioid epidemic from all angles. Her book also details her conversations with a drug dealer named Ronnie Jones, who “ran one of the largest heroin rings in the mid-Atlantic region,” according to NPR.

    Jones had tried a few times to recreate his life after spending time in jail, but with little luck.

    “Ronnie’s story illustrates how little we do for felons trying to re-enter our society. You know, we don’t make it easy for them to get jobs,” Macy told NPR. “They often come out, and they owe lots of fines. And he tries to go legit. And he ends up—you know, he starts out selling weed again, which he had been selling before. But meanwhile, since he’s been in prison, this opioid thing has exploded. And somebody tells him in the break room of George’s Chicken, hey, man, if you want to make the real money, you need to be bringing heroin in.”

    Also in her book, Macy examines the role that Purdue Pharma (the manufacturer of OxyContin) has played in the epidemic. She states that when Purdue introduced OxyContin, it was marketed as being more safe than other painkillers because of its 12-hour time release mechanism.

    For the past three years, Macy says, she has been following Google alerts for articles pertaining to the opioid crisis. However, she says, none of them addressed every angle of the crisis as she hoped to.

    “Each of them only deal with a little piece of something going on right now,” she tells NPR. “And my goal with this book was not to just show you how we got here and what it’s going to take to get out of it, but also to inspire people to care. And I really hope that that’s what I’ve done.”

    View the original article at thefix.com

  • Purdue Pharma Reportedly Worried About Losing Money To Rivals Amid Oxy Panic

    Purdue Pharma Reportedly Worried About Losing Money To Rivals Amid Oxy Panic

    A new report details the early rivalry among opioid drug makers who sought to follow in the profitable footsteps of Purdue Pharma.

    As Purdue Pharma came under fire from federal investigators for unscrupulous advertising practices, the company was reportedly concerned about losing market share to other drug manufacturers, according to internal documents. 

    “Market research as well as reports from the sales force indicates that methadone use is increasing in both the management of cancer pain and non-malignant pain due to its low cost,” an internal Purdue memo from 1999 said, according to a report by Kaiser Health News

    OxyContin was brought to market in 1996, and by 1999 Purdue was planning to expand sales into the non-cancer market, setting the stage for marketing practices that would later land the company in lawsuits across the country for false and misleading advertising.

    As part of the planned expansion, Purdue reportedly analyzed the market for pain medications in internal documents. 

    According to these internal documents, one competitor that Purdue was most concerned about was Janssen Pharmaceuticals, the maker of Duragesic, a fentanyl patch.

    Purdue noted that Janssen, a part of Johnson & Johnson, was making “slow but steady” progress in marketing the patches.

    In fact, Janssen tripled its advertising spending between 1998 and 1999 as regulators and clinicians first became aware of the dangers of OxyContin. Marketing materials from that time included the claims that the patch “has less potential for abuse than other currently available opioids.”

    By 2000, the Food and Drug Administration noted that Janssen had disseminated “false or misleading” advertising, including that safety claim.

    Despite Purdue’s own claims about the safety of its drugs, the company was allegedly quick to acknowledge the trouble that the competition was in. 

    “It has been reported that Janssen sales representatives are using improper techniques to capitalize on the negative press surrounding OxyContin tablets and the issue of abuse and diversion,” Purdue marketing materials noted in 2002. 

    At the same time, Purdue noted that methadone was claiming market share for pain patients, despite the 2006 FDA warning of deaths and dangerous side effects in “newly starting methadone for pain control and in patients who have switched to methadone after being treated for pain with other strong narcotic pain relievers.” 

    In a statement to Kaiser Health News, Janssen said that the marketing procedures for the fentanyl patch were “appropriate and responsible,” and that the company “acted quickly to investigate and successfully resolve FDA’s inquiries.”

    Janssen stopped “actively marketing” Duragesic in 2008. 

    Purdue has also denied false or misleading advertising, telling Kaiser, “We vigorously deny these allegations and look forward to the opportunity to present our defense” in a series of lawsuits. 

    View the original article at thefix.com

  • Purdue Pharma Knew About Oxy Misuse Early On, Report Finds

    Purdue Pharma Knew About Oxy Misuse Early On, Report Finds

    The report also alleges that in 1999 company officials learned of a call to a pharmacy describing “OxyContin as the hottest thing on the street—forget Vicodin.”

    Purdue Pharma reportedly knew that the opioid pill OxyContin was being snorted and sold on the street as early as 1999, just three years after the medication’s release.

    However, the company reportedly kept quiet about this knowledge and continued marketing the drug as a safer pain-relief pill.

    The New York Times obtained a confidential Justice Department report that was compiled in the early 2000s, leading up to Purdue’s settlement with the federal government in 2007.

    Purdue executives have testified in Congress that they did now know that the product was being abused until the United States attorney in Maine issued a warning in 2000. 

    “Everyone was taken by surprise by what happened,” Purdue’s top medical officer, Dr. Paul D. Goldenheim, testified in 2001. “We launched OxyContin in 1996, and for the first four years on the market, we did not hear of any particular problem.” 

    However, the Justice Department report shows that this is not true.  

    “We have in fact picked up references to abuse of our opioid products on the internet,” Purdue Pharma’s general counsel, Howard R. Udell, wrote in early 1999 to another company official.

    The report also alleges that in 1999 company officials learned of a call to a pharmacy describing “OxyContin as the hottest thing on the street—forget Vicodin.”

    Federal prosecutors also found the words “street value,” “crush,” or “snort” in 117 internal notes that recorded meetings between Purdue representatives and doctors before 2000.

    The report’s findings were so alarming that prosecutors recommended that felony charges be brought against three of Purdue’s executives. However, Justice Department officials under George W. Bush did not support that and ended up brokering a settlement in 2007 that avoided felony criminal charges and allowed Purdue to continue selling OxyContin

    Now, some people see this as a missed opportunity. 

    “It would have been a turning point,” said Terrance Woodworth, a former Drug Enforcement Administration official who investigated Purdue Pharma in the early 2000s. “It would have sent a message to the entire drug industry.”

    However, another former DEA official told The New York Times that U.S. Attorney John Brownlee ultimately felt that accepting a deal would be best because Purdue had so many resources available to aid in its defense, including the expertise of Rudy Giuliani, who helped craft the deal for Purdue. 

    “He told me he was outgunned,” Joseph Rannazzisi said. 

    Brownlee has said that he felt the deal reached in 2007 was appropriate, but that he thought it would trigger tighter oversight of Purdue, something that did not happen. 

    “I didn’t feel as a lawyer I could be in a position to bar anyone from getting OxyContin. Faced with that decision, I was just simply not prepared to take it off the market. I didn’t feel like that was my role,” he said. “My role was to address prior criminal conduct. Hold them accountable. Fine them. Make sure the public knew what they did.”

    View the original article at thefix.com

  • Massive Drug Spoon Sculpture Dropped At Purdue Pharma HQ

    Massive Drug Spoon Sculpture Dropped At Purdue Pharma HQ

    The message behind the guerrilla art exhibit is to call attention to the potential danger of prescription opioids.

    A gallery owner was arrested Friday morning (June 22) after placing a sculpture of a massive steel spoon at the headquarters of Purdue Pharma, the maker of OxyContin.

    Fernando Louis Alvarez was arrested and charged with obstruction of free passage, a criminal misdemeanor. The sculpture was displayed in front of the Stamford, Connecticut office for about two hours until it was hauled away by city workers.

    The 800-pound, 10.5-foot-long work of “guerrilla art” appears burnt and bent at the handle, a sight familiar to people who heat up and inject heroin. The artist, Domenic Esposito, of Westwood, Massachusetts, described how his family was affected by his brother Danny’s nearly 14-year addiction to heroin, which began with OxyContin and Percocet.

    “My mom would call me in a panic… screaming she found another burnt spoon. This is a story thousands of families go through. He’s lucky to be alive,” he said, according to the Hartford Courant.

    “The spoon has always been an albatross for my family. It’s kind of an emotional symbol, a dark symbol for me,” he added.

    The message behind the art exhibit is to call attention to the potential danger of prescription opioids, and to call on the federal government to “step in and do something,” Esposito said. Danny has been sober for the last four months.

    Purdue Pharma is among several pharmaceutical companies being targeted by lawsuits across cities, counties, and states that believe these entities had a hand in worsening the opioid crisis. Purdue, specifically, is accused of using deceptive marketing and downplaying the risk of addiction to promote OxyContin.

    The company has since announced that it will no longer market OxyContin to doctors, and just last week, laid off its entire sales team.

    Purdue released a statement on Friday regarding Esposito’s sculpture: “We share the protestors’ concern about the opioid crisis, and respect their right to peacefully express themselves. Purdue is committed to working collaboratively with those affected by this public health crisis on meaningful solutions to help stem the tide of opioid-related overdose deaths.”

    The night of the guerrilla art display, Alvarez hosted the opening of a full exhibit on the opioid crisis at his art gallery in Stamford.

    The spoon has reportedly been submitted as evidence.

    View the original article at thefix.com

  • Accused Dark Web Kingpin "OxyMonster" Faces 20-Year Sentence

    Accused Dark Web Kingpin "OxyMonster" Faces 20-Year Sentence

    Federal agents captured the accused drug kingpin when he came to the US for a beard contest last summer.

    The man who is accused of selling oxycodone, cocaine and methamphetamine online under the alias “OxyMonster” will reportedly plead guilty in federal court on charges of drug conspiracy and money laundering, the Associated Press reported on Thursday (May 31).

    Guy Vallerius faces at least 20 years in prison. The alleged dark web drug dealer was nabbed by U.S. authorities while en route from France to Austin, Texas last summer for the World Beard and Moustache Championships. He was planning to compete in the “full beard 30.1-45cm” category.

    DEA special agent Lilita Infante had Vallerius on her radar when she requested Homeland Security border officials to detain him for questioning upon his arrival in Atlanta, Georgia, his first stop from Paris.

    Infante was hoping he’d have a laptop with him, which he did. Authorities searched his computer and was able to “directly link Vallerius to the Dream Market,” the dark web marketplace where Vallerius would “moderate sales of cocaine, methamphetamine and oxycodone,” according to the AP

    According to a DEA affidavit issued last August, authorities were able to “confirm his identity as ‘OxyMonster’” following the border search of his laptop, on which agents discovered the Tor browser (allowing one to conceal their true IP address that would be able to identify them), “apparent log-in credentials for Dream Market, and $500,000 worth of bitcoin.”

    The affidavit states that Vallerius’ online profile advertised that he shipped his illicit wares from France to anywhere in Europe and the United States.

    Vallerius also had a drug vendor page on a similar dark web marketplace called TradeRoute, according to DEA officials, where he had been a member since February 2017, according to the affidavit.

    A magistrate judge stated in a summary of the prosecution’s case:

    “In connection with his role as a ‘senior moderator,’ (Vallerius) also sold controlled substances to other members using the website, receiving payment for these sales through the use of bitcoin ‘tip jar,’ or electronic depository. It was through this tip jar that law enforcement officials became aware of Vallerius’ true identity.

    “After locating the bitcoin depository allegedly belonging to the user ‘OxyMonster,’ agents tracked several incoming payments and outgoing deposits from the tip jar to various ‘wallets’ controlled by Vallerius.”

    Vallerius’ upcoming court hearing on his plea deal is scheduled for June 12.

    View the original article at thefix.com